Fimex Co., Ltd. was selected as No. 2 in the world by KPMG Private Enterprise’s Global Tech Innovator 2022

Fimex Co., Ltd.
Fimex Co., Ltd. was selected as No. 2 in the world by KPMG Private Enterprise’s Global Tech Innovator 2022

Fimex Co., Ltd. (Headquarters: Fujisawa City, Kanagawa Prefecture; Representative Director: Yusuke Tominari; hereinafter “our company”) is pleased to announce that KPMG Private Enterprise’s Global Tech Innovator 2022 (hereinafter “this event”) was held in Lisbon, Portugal on November 2nd. ”), Kanae Kaba, our co-founder and CSO, took the stage as a representative of Japan and won second place.
In this event, startups from 22 countries that won the qualifying round participated in the event, and pitches were held for startups that made full use of the latest technologies such as AI, life sciences, health tech and fintech.
[Image 1

Kanae Kaba, Director and CSO of the Company, said: “I am very honored to receive the second prize in the global competition and to think that my enthusiasm for delivering innovative medicines to patients has been recognized. We will continue to work hard to expand our opportunities.”
[About Fimex]
Fimex is a drug discovery venture company that promotes the research and development of new pharmaceuticals whose mechanism of action is protein degradation. Based on our unique E3 ligase-binding molecule and drug discovery platform technology “RaPPIDS(TM)”, we have developed several first- We are promoting an in-class new drug development program. By using RaPPIDS(TM) not only for internal projects, but also for joint research with companies and research institutes in Japan and overseas, we will address a wide range of drug targets and unmet medical needs, and provide benefits to patients and families around the world. We will provide life-saving medicine of
[About RaPPIDS(TM)]
RaPPIDS(TM) (Rapid Protein Proteolysis Inducer Discovery System) is a basic drug discovery technology for rapidly discovering proteolysis inducers. Our proprietary know-how and Diversity Oriented Synthesis enable us to rapidly search and evaluate the optimal combination of target protein-binding molecules, linkers, and E3 ligase-binding molecules, which are the components of proteolytic inducers. Furthermore, the application of RaPPIDS(TM) will enable the search for novel E3 ligase-binding molecules that can be used as proteolysis inducers, enabling the degradation of a wider range of target proteins.
[Image 2

In 2009, completed the master’s course at the Graduate School of Pharmaceutical Sciences, Osaka University. Joined Takeda
Pharmaceutical Co., Ltd. in the same year. Engaged in drug discovery research in the fields of cancer and immunology as a biologist. In 2018, co-founded Fimex Co., Ltd. with colleagues from Takeda Pharmaceutical Company Limited. Vice President of Biology at the company. Completed doctoral course at University of Tsukuba in 2020 (Ph.D.). Director and CSO from 2021 (current position). 3 substance patents, 8 papers and other publications.

[Inquiries regarding this matter]
Fimex Co., Ltd.
2-26-1 Muraokahigashi, Fujisawa City, Kanagawa Prefecture
E-mail: Tel: 0466-96-0261
Details about this release:


Leave a Reply

Your email address will not be published.

%d bloggers like this: